

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and is Active in Refractory T Cell Lymphomas

Ryan Wilcox, MD, PhD

Section Head, Lymphoma & Myeloma

Associate Professor, Department of Internal Medicine, Division of Hematology/Oncology
University of Michigan

Yuqin Song¹, Ning Ding¹, Dok Hyun Yoon², John Reneau³, Ryan Wilcox⁴, Won Seog Kim⁵, Youn Kim⁶, Michael Khodadoust⁶, Tatyana Feldman⁷, Costas K Yannakou⁸, Pratyush Giri⁹, Jonathan Brammer³, Lih-Yun Hsu¹⁰, Hongwei Yuan¹⁰, Erik Verner¹¹, Suresh Mahabhashyam¹⁰, Richard Miller^{10,11}

¹Peking University Cancer Hospital & Institute, Beijing, China; ²Asan Medical Center, Seoul, South Korea; ³The Ohio State University and Wexner Medical Center, Columbus, OH, USA; ⁴University of Michigan, Ann Arbor, MI, USA; ⁵Samsung Medical Center, Seoul, South Korea; ⁶Stanford Cancer Institute, Stanford, CA, USA; ⁷John Theurer Cancer Center at HMH, Hackensack, NJ, USA; ⁸Epworth HealthCare, Melbourne, Victoria, Australia; ⁹Royal Adelaide Hospital, Adelaide, South Australia, Australia; ¹⁰Corvus Pharmaceuticals Inc, Burlingame, CA, USA; ¹¹Angel Pharmaceuticals Co., Ltd, Jiaxing, China

Introduction

- ITK (IL-2 inducible T cell kinase) is expressed in T cells with an important role in T cell receptor signaling and T helper cell differentiation.
- Resting lymphocyte kinase (RLK) is a closely related kinase involved in the differentiation of naïve T cells into Th1 T cells
- ITK^{-/-} mice exhibit defects in Th2 differentiation while retaining the ability to differentiate into Th1 cells that secrete INF γ
- Th1 cells are involved in cytotoxic T cell functions such as destruction of tumor cells; Th2 cells play a role in various inflammatory processes.
- CPI-818 is a covalent inhibitor of ITK (KD 2.5nM) with > 100 fold selectivity over RLK
- CPI-818 is being evaluated in an ongoing phase 1 trial in refractory peripheral T cell lymphomas

ITK Plays Critical Roles in T Helper Cell Differentiation

ITK involved in many diseases


CPI-818 is selective for ITK

Closely related Tec Kinases

	CPI-818 K_D^* (nM)
ITK	2.5
BLK	4700
BMX	9100
BTK	1200
EGFR	>10000
ERBB2	>10000
ERBB4	>10000
JAK3	2800
MKK7	>10000
TEC	540
RLK	2700

* Dissociation constants

ITK blockade leads to increase in Th1 and reduction in Th2, Th17



Methods and Trial Design

IN VITRO AND PRECLINICAL STUDIES



- **Serum cytokines** measured using MSD immunoassay format
- **Lymphocyte subsets** enumerated using flow cytometry on peripheral blood and tumor biopsy specimens using antibodies to CD3, 4, 8, 183, 196, 197 and 45RA
- C57BL/6 mice with established EL4 murine T cell lymphoma (CD4+/CD8-) were treated with CPI-818

PHASE 1 CLINICAL TRIAL IN REFRACTORY PERIPHERAL T CELL LYMPHOMAS

- **Eligibility:** failed all standard prior therapies
- **Histologies:** cutaneous T-cell lymphoma (CTCL), angioimmunoblastic T-cell lymphoma (AITL), peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), anaplastic large-cell lymphoma (ALCL), and extranodal natural killer/T-cell lymphoma (ENKTCL)
- **Design:** successive cohorts of patients received CPI-818 100 mg, 200 mg, 400 mg, or 600 mg PO BID
- **Endpoints:** safety, immunologic activity and tumor response

Treatment of Murine EL4 T Cell Lymphoma with CPI-818

Tumor growth inhibition and increases in CD8+ T cell infiltration




Mice with established EL4 tumors (CD4+) were treated with CPI-818 10, 30 mg/kg or vehicle daily for 7 days and tumor measurements/excision were made at Day 22 (3 days after dosing). Treatment groups were compared to control. Tumors were removed and immunohistochemistry was performed to enumerate infiltrating CD8+ normal T cells.


CPI-818 induces Th1 skewing *in vitro* in Normal PBMC

Concentration dependent effects

Th1 cells (ratio IFN γ :IL-4) dose response effect in vitro



High concentrations block T cell proliferation in vitro



Normal PBMC from 12 healthy donors were stimulated in vitro with anti-CD3/CD28 in the presence of various concentrations of CPI-818. Intracellular interferon gamma and IL-4 were measured using flow cytometry and Th1 skewing was determined by interferon gamma:IL-4 ratio. Effects on cell proliferation and viability were also determined. These results indicate that concentrations >0.01 and $<10 \mu\text{M}$ induce Th1 skewing with anti-proliferative effects seen $\geq 1 \mu\text{M}$.

Phase I Trial Pharmacokinetic Analysis

Dose of 200mg achieves levels needed for Th1 skewing

In vivo CPI-818 Plasma Concentration mM*


Dose (mg)	C _{max} (Std Dev)	C _{min} (Std Dev)
100 (N=4)	1.3 (1.0)	0.04 (0.1)
200 (N=5)	2.3 (1.9)	0.09 (0.2)
400 (N=5)	4.0 (2.3)	0.5 (1.1)
600 (N=11)	5.5 (4.7)	0.4 (0.6)

* Geometric mean

- PK studies indicate 200 mg dose provides optimum plasma concentration for Th1 skewing.
- Other studies on peripheral blood T cells showed that doses of 200 mg and higher provide maximal ITK target occupancy.

Effects of CPI-818 on In Vitro T Cell Cytokine Production

CPI-818 inhibits Th2 cytokine production from normal CD4+ and Sezary cells



FACS-sorted CD4+ T cells from healthy controls (n=3; top panel) or from Sezary patients (n=2; bottom panel) were activated with anti-CD3/CD28/CD2-coated beads in the absence or presence of varying concentrations of CPI-818 for 72 hours. Supernatants were collected and Th2-associated cytokines, IFN γ , and TARC (CCL17) were measured.

Interim Phase 1 Trial Results


Patient characteristics and adverse event summary

	100mg (N=4)	200mg (N=13)	400mg (N=10)	600mg (N=16)
Age (yrs), median (range)	51 (29, 75)	59 (29, 81)	66.5 (36, 80)	63.5 (34, 84)
Gender, male N (%)	3 (75)	4 (31)	6 (60)	8 (50)
No. of prior therapies, median (range)	3.5 (2, 4)	3 (1, 6)	4 (2, 15)	5 (1, 9)
Histologies				
PTCL- NOS	1	7	3	9
Angioimmunoblastic T cell lymphoma	1	4	2	0
Adult T cell leukemia/lymphoma	1	0	0	0
Anaplastic large cell lymphoma	1	1	0	0
T-PLL	0	0	0	1
CTCL (Sézary syndrome)	0	1	4	1
CTCL (Mycosis fungoides)	0	0	1	5

Most common ($\geq 10\%$, all causality) AEs: nausea, chills, vomiting, fatigue, pyrexia, decreased appetite, pruritus, and rash. Treatment-related Grade 3+ AEs: anemia (1), lymphocytosis (1), WBC decreased (1) and neutropenia (1).

Anti-tumor Activity in Various Dosing Cohorts

200 mg BID identified as optimal dose with ORR of 4/11 evaluable



Anti-tumor Activity in Refractory Disease

Regression of large tumor masses observed



Screening




Day 15

- PTCL-NOS patient failed CHOEP, GDP, HDACi, and anti-PD1.
- Large subcutaneous mass on abdomen.
- Has PR 8+ months duration in all sites of disease (bone marrow, skin, lymph node, and spleen) on CPI-818.


Immunologic Effects in Treated Patient

Optimum dose induces Th1 skewing and Th2 blockade



Frequency of Th1 & Th17 CD4 cells in Blood



Effects on Eosinophils and Serum IL-5




Th1 and CD4+ Effector Cells Increase in Blood and Tumor During CPI-818 Treatment



PBMC and tumor samples were analyzed at various timepoints and demonstrate increase in blood Th1, decrease in blood Th17, reduction of both eosinophil count and IL-5 consistent with Th1 skewing and Th2 blockade. Baseline and on treatment tumor biopsy and blood show increase in Th1 and terminally differentiated T effector memory cells.

Effects of CPI-818 on Differentiation of Th1 and CD8+ TEMRA Cells

Percent Change in Th1 and CD8+ TEMRA Cells from Baseline



Peripheral blood from four patients were collected at various timepoints and T cell subsets evaluated by flow cytometry. Plots show percent change from baseline for Th1 (CD3+/CD4+/CD8-/CD183+/CD196-) and for CD8+ TEMRA (CD3+/CD4-/CD8+/CD197-/CD45RA+). Two PR patients and SD patient show increases in Th1 and TEMRA cells while on treatment with CPI-818. Of note, the SD and PD patients were lymphopenic at baseline (<1000 ALC).

Conclusions

- CPI-818 is a selective ITK inhibitor that at optimal concentrations induces Th1 skewing and blockade of Th2 function and related cytokine production (e.g., IL-4, IL-5, IL-13, TARC).
- In an ongoing international Phase 1 trial:
 - Durable objective responses seen (1 CR, 25 mo; 1 nodal CR, 19 mo; 2 PRs, 6+, 8+ mo) in 11 evaluable patients at optimum dose.
 - Doses up to 600 mg po BID have been well-tolerated with no DLT.
 - Treatment induces Th1 skewing and Th2/Th17 blockade in vivo.
 - Baseline and on-treatment blood and tumor biopsy specimens show increases in both Th1 cells (CD3+/CD4+/CD8-/CD183+/CD196-) and in terminally differentiated T effector memory cells (TEMRA: CD3+/CD4-/CD8+/CD197-/CD45RA+).
- The increases in Th1 cells and TEMRA CD8+ cells in humans and preclinical data suggest that anti-tumor activity is due to induction of a host anti-tumor response.
- Selective ITK inhibition may have the potential to enhance anti-tumor immunity and also could be useful in the therapy of Th2-mediated autoimmune/allergic diseases.
- A Phase 2 trial in refractory peripheral T cell lymphomas is planned.

Acknowledgements

- Participating Centers and Investigators:



We thank the patients and their families.